1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Supriya Lifescience Limited

Supriya Lifescience Limited

SUPRIYA.BO
Supriya Lifescience LimitedIN flagBombay Stock Exchange
901.75
INR
-15.15
- -
72.58BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
108.75
121.99
150.84
64.53
56.04
69.26
86.52
102.85
102.85
Basic EPS, GAAP
15.43
28.73
48.38
18.86
11.16
14.8
23.35
25.98
25.98
Free Cash Flow per Basic Share
16.33
35.83
10.82
-1.38
-5.5
-4.02
0.29
4.17
- -
Dividend per Share
- -
6.91
1.55
0.55
0.6
0.6
0.8
1
- -
Book Value per Share
36.71
58.4
105.04
51.84
62.41
76.61
99.14
2
2
Tangible Book Value per Share
35.93
57.15
104.5
76.31
86.78
101.1
123.65
148.64
148.63
Basic Weighted Avg Shares
26
26
26
80
80
80
80
80
80
Sales/Revenue/Turnover
2,778
3,116
3,854
5,194
4,510
5,574
6,965
8,279
8,279
Operating Margin (%)
23.42
32.34
42.67
38.92
25.57
28.3
34.51
32.09
32.09
Depreciation Expense
54
64
68
101
118
158
204
284
284
Net Income, GAAP
394
734
1,236
1,518
899
1,191
1,880
2,091
2,091
Effective Tax Rate (%)
30.96
23.72
26.13
26.75
27.23
28.11
24.36
23.9
23.89
Profit Margin (%)
14.19
23.55
32.07
29.23
19.92
21.37
26.99
25.26
25.26
Working Capital
-20
426
1,194
3,978
3,691
3,209
3,549
4,113
4,113
LT Debt
107
47
21
53
55
50
51
52
52
Total Equity
938
1,492
2,686
6,157
6,995
8,154
9,968
11,977
11,977
Return on Invested Capital (%)
- -
36.16
40.13
29.09
12.22
14.7
20.04
18.38
18.38
Return on Capital (%)
- -
37.45
43.79
39.19
18.79
21.24
26.55
51.05
51.05
Return on Common Equity (%)
- -
60.42
59.2
44.29
19.54
21.29
26.57
51.37
51.37

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
3
- -
2
LT Borrowings
- -
- -
- -
LT Finance Leases
49
- -
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
- -
80
Market Capitalization
58,550
60,302
45,487

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,051
- -
5,323
Cash, Cash Equivalents & STI
1,062
- -
789
Accounts Receivable, Net
1,551
- -
2,194
Inventories
1,428
- -
1,596
Total Current Liabilities
829
- -
1,210
Payables & Accruals
- -
- -
- -
ST Debt
3
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
40.37%
20.16%
Free Cash Flow
- -
276.68%
1,358.63%
Net Income, GAAP
- -
16.73%
11.26%
Sales/Revenue/Turnover
- -
17.8%
18.86%
Total Cash Common Dividend
- -
- -
24.99%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,320
1,401
1,401
1,452
5,574
2025
1,606
1,661
1,856
1,841
6,965
2026
1,451
1,998
2,064
2,765
8,279

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.54
2.97
3.7
- -
14.8
2025
5.54
5.71
5.82
6.29
23.35
2026
4.32
6.27
6.17
9.22
25.98

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
1

Company Description

APIChat
CEO
Satish Waman Wagh
Full Time Employees
448
Sector
Healthcare
Industry
Biotechnology
Address
207/208 Udyog Bhavan Mumbai India 400063
IPO Date
Dec 28, 2021
Website
supriyalifescience.com
Similar Companies
Insmed Incorporated (0JAV.L)
Santhera Pharmaceuticals Holding AG (0QN1.L)
Jaguar Health, Inc. (JAGX)
Syngene International Limited (SYNGENE.BO)
Alpine Immune Sciences, Inc. (ALPN)
La Jolla Pharmaceutical Company (LJPC)
Business
Supriya Lifescience Limited is dedicated to the research, development, production, and worldwide distribution of active pharmaceutical ingredients and specialty chemicals. The company offers a diverse range of products spanning multiple therapeutic areas, including antihistamines, antiasthmatics, decongestants, analgesics, anesthetics, and essential vitamins. With a robust portfolio of over 38 specialized APIs, including 15 backward-integrated products, it serves a global customer base across more than 120 countries, with a significant portion of its revenue derived from exports to regulated markets like Europe and Asia. Established in Mumbai, India, in 1987, and incorporated as a public limited company in 2008, Supriya Lifescience operates state-of-the-art manufacturing facilities with international regulatory approvals, emphasizing backward integration for supply chain control and cost efficiency. Recent developments include the inauguration of a new production block (Module E) in late 2024 to expand capacity and support new product launches, such as a recent anesthetic API. The company is also strategically expanding into Contract Development and Manufacturing (CDMO) services, contrast media, and nutraceuticals, targeting substantial future growth.